Jefferies is out with its report today on Charles River Laboratories CRL, lowering its PT from $40 to $33.
In its report, Jefferies writes, "We are lowering our PT to $33, or 12.5x our 2012 EPS estimate of $2.65. This is an overly steep reduction under normal circumstances. However, to warrant buying in the midst of this risk-off trade, we suggest that stocks should have clearer visibility to growth and/or unlevered balance sheets."
Jefferies maintains Hold on CRL.
Shares of CRL closed Monday at $28.82, down 12.11% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareJefferiesLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in